clinical trial · NCT06908707
A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women
PostmenopausalHealthy Adult Female ParticipantsLAE102 SCPlacebo SCLAE102 IVPlacebo IV
brief summary
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of LAE102 in healthy postmenopausal women
started
Apr 22, 2025
primary completion
Oct 23, 2025
completion
Oct 23, 2025
last updated
Nov 17, 2025
detailed description
This is a placebo-controlled single ascending dose by subcutaneous (SC) and Intravenous (IV) administration in healthy postmenopausal women to assess the safety and tolerability of LAE102. At least 32 healthy female participants will be enrolled in 4 cohorts with each cohort including 8 participants randomized 6:2 LAE102:Placebo.
official title
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Phase 1 Study to Determine the Safety, Tolerability and Pharmacokinetics of LAE102 in Healthy Postmenopausal Women
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol